Cholesterol screening should be targeted

American Journal of Medicine

Volumn 102, Issue 2 A, 1997, Pages 26-30

  Garber, Alan M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

CORONARY RISK; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; SECONDARY PREVENTION;

EID: 0030991408     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00464-6     Document Type: Article

References (18)

1. Garber AM, Browner WS. American College of Physicians Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med. 1996;124:515-517.
2. Garber AM, Browner W, Hulley S. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med. 1996;124:518-531.
3. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335-1340.
4. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383-1389.
6. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
7. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med. 1993;153:1065-1073.
8. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176-2180.
9. Davis C, Rifkind B, Brenner H, Gordon D. A single cholesterol measurement underestimates the risk of CHD. JAMA. 1990;264:3044-3046.
10. Brown G, Abers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apoprotein B. N Engl J Med. 1990;323:1289-1298.
11. Watts GF, Lewis B, Brunt JNH, et al. Favorable effects on coronary artery disease of lipid lowering diet or diet and cholestyramine in a unifactorial randomised controlled trial: the STARS study. Lancet. 1992;339:563-569.
12. Law MR, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? Br Med J. 1994;308:367-373.
13. Collins R, Peto R, MacMahon S, et al. Short-term reductions in blood pressure: overview of randomised trials. Lancet. 1990;335:827-838.
14. Family Heart Study Group. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Br Med J. 1994;308:313-320.
15. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. Br Med J. 1995;310:1099-1104.
16. United States Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore, MD: Williams & Wilkins, 1996.
17. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. Br Med J. 1991;303:953-957.
18. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Anti-hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (AL-LHAT). Am J Hypertens. 1996;9:342-360.